Genzyme appoints M&F to handle kidney drug programme

Biotech company Genzyme has appointed Munro & Forster to handle a European PR programme for its kidney drug Renagel.

Renagel is a treatment for patients on kidney dialysis, which prevents a damaging build-up of phosphate in arterial walls.

M&F’s head of international healthcare Ellen Sarewitz will head up the account reporting into Genzyme’s Renal Business Unity European marketing manager Kate Gribbon.

‘This is the first time that Genzyme’s EU Renal team has used a PR agency for a product-specific PR campaign,’ said Gribbon.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.